Schott Pharma AG KGaA (FRA:1SX) EBIT: €202.6 Mil (TTM As of Mar. 2026)


FRA:1SX Schott Pharma AG & CO KGaA FRA:1SX
64 GF Score
Price €4.04
GF Value €6.49
! 2 Warning Signs
View Full Analysis

What is Schott Pharma AG KGaA EBIT?

Schott Pharma AG KGaA FRA:1SX -0.98% 64 EBIT is €202.6 Mil as of Mar. 2026. GuruFocus rates FRA:1SX with a GF Score™ of 64/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review.

Schott Pharma AG KGaA's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €44.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €202.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Schott Pharma AG KGaA's annualized ROC % for the quarter that ended in Mar. 2026 was 9.72%. Schott Pharma AG KGaA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 22.21%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Schott Pharma AG KGaA's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 7.58%.


Schott Pharma AG KGaA  (FRA:1SX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Schott Pharma AG KGaA's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=158.192 * ( 1 - 22.76% )/( (1246.624 + 1266.736)/ 2 )
=122.1875008/1256.68
=9.72 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1627.782 - 349.025 - ( 32.133 - max(0, 442.715 - 698.997+32.133))
=1246.624

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1610.038 - 310.953 - ( 32.349 - max(0, 421.708 - 669.218+32.349))
=1266.736

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Schott Pharma AG KGaA's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=177.288/( ( (792.352 + max(-26.039, 0)) + (804.142 + max(-38.781, 0)) )/ 2 )
=177.288/( ( 792.352 + 804.142 )/ 2 )
=177.288/798.247
=22.21 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(204.995 + 182.526 + 29.155) - (349.025 + 0 + 93.69)
=-26.039

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(172.411 + 181.067 + 29.449) - (310.953 + 0 + 110.755)
=-38.781

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Schott Pharma AG KGaA's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=202.645/2673.918
=7.58 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Schott Pharma AG KGaA EBIT Related Terms


Schott Pharma AG KGaA EBIT Historical Data

* Premium members only.

The historical data trend for Schott Pharma AG KGaA's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Schott Pharma AG KGaA EBIT Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial 124.96 160.97 193.06 197.46 207.77

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.43 65.05 47.23 46.04 44.32

FRA:1SX vs ISRG, BDX, MDLN: EBIT Comparison

For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Schott Pharma AG KGaA EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Schott Pharma AG KGaA's EV-to-EBIT falls into.


FRA:1SX
64GF Score
Schott Pharma AG & CO KGaA FRA:1SX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Schott Pharma AG KGaA EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €202.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €202.6 Mil mean?
Schott Pharma AG KGaA (FRA:1SX) has a EBIT of €202.6 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Schott Pharma AG KGaA.
Is Schott Pharma AG KGaA's EBIT too high?
Schott Pharma AG KGaA's current EBIT is €202.6 Mil. Overall, Schott Pharma AG KGaA has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's EBIT compare to ISRG and BDX?
Schott Pharma AG KGaA's EBIT of €202.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Schott Pharma AG KGaA. Schott Pharma AG KGaA's current EBIT is €202.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current EBIT of €202.6 Mil. The stock's GF Value™ is €6.49, compared to a current price of €4.04 — trading 37.8% below its estimated fair value. The current EBIT is €202.6 Mil. Schott Pharma AG KGaA's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current EBIT is €202.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?

Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued. The current stock price of €4.04 is trading 37.8% below its estimated GF Value™ of €6.49.

Key valuation signals for FRA:1SX:

  • EBIT: €202.6 Mil
  • GF Value™: €6.49 vs. price of €4.04 (37.8% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Schott Pharma AG KGaA Business Description

Address Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
64GF Score

Get the complete analysis for FRA:1SX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.04
Price
€6.49
GF Value